Headlines about Geron Corporation (NASDAQ:GERN) have trended somewhat positive this week, according to Accern. The research group identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Geron Corporation earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 47.3281534496029 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the news articles that may have impacted Accern’s scoring:

Several research firms have recently commented on GERN. FBR & Co reaffirmed a “buy” rating on shares of Geron Corporation in a research report on Tuesday, July 4th. BidaskClub downgraded Geron Corporation from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Finally, Zacks Investment Research raised Geron Corporation from a “hold” rating to a “buy” rating and set a $2.50 target price on the stock in a research report on Tuesday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. Geron Corporation presently has a consensus rating of “Hold” and a consensus price target of $3.75.

Geron Corporation (NASDAQ GERN) traded down 0.86% during trading on Friday, hitting $2.30. The stock had a trading volume of 884,634 shares. Geron Corporation has a 1-year low of $1.81 and a 1-year high of $3.15. The firm has a 50 day moving average price of $2.15 and a 200-day moving average price of $2.48. The firm’s market capitalization is $366.19 million.

Geron Corporation (NASDAQ:GERN) last released its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. Geron Corporation had a negative net margin of 433.72% and a negative return on equity of 21.30%. The business had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.38 million. During the same period in the previous year, the business earned ($0.05) EPS. Geron Corporation’s revenue was down 19.0% compared to the same quarter last year. On average, equities research analysts expect that Geron Corporation will post ($0.18) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/10/06/geron-corporation-gern-given-daily-news-sentiment-score-of-0-15.html.

About Geron Corporation

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.

Insider Buying and Selling by Quarter for Geron Corporation (NASDAQ:GERN)

Receive News & Ratings for Geron Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron Corporation and related companies with MarketBeat.com's FREE daily email newsletter.